Literature DB >> 7924685

Simultaneous analysis of c-erbB-2 expression and DNA content in breast cancer using flow cytometry.

O Stål1, S Sullivan, X F Sun, S Wingren, B Nordenskjöld.   

Abstract

The c-erbB-2 oncogene is frequently amplified and overexpressed in human breast cancer. We have studied the c-erbB-2 protein in conjunction with DNA content in frozen samples from breast cancers using flow cytometry. The cell suspensions were obtained by mechanical disaggregation followed by a short fixation in 1% paraformaldehyde. The level of c-erbB-2 expression was calculated as a fluorescence index, taking into account the relative amount of total cellular fluorescence compared to nonspecific fluorescence. The flow cytometric value correlated with immunohistochemical results obtained with the same monoclonal antibody (c-neu, clone 9G6). Overexpression of c-erbB-2 was significantly more frequent in DNA aneuploid tumors than in DNA diploid ones and correlated with increasing S-phase fraction and estrogen receptor negativity. In 10 DNA multiploid tumors, the different aneuploid stemlines uniformly expressed c-erbB-2, supporting the hypothesis that overexpression is an early event in breast cancer. Of the 172 tumors, the 37 (22%) judged as positive with immunohistochemistry showed a somewhat higher rate of distant recurrence than others (P = 0.14). The fluorescence index was significantly associated with prognosis (P = 0.0012), as it was also among the immunohistochemically positive cases. If the degree of overexpression is important, then flow cytometry could be a feasible technique for classification.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7924685     DOI: 10.1002/cyto.990160210

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  5 in total

1.  Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients.

Authors:  G Pérez-Tenorio; O Stål
Journal:  Br J Cancer       Date:  2002-02-12       Impact factor: 7.640

2.  Are fine-needle breast aspirates representative of the underlying solid tumour? A comparison of receptor levels, ploidy and the influence of cytokeratin gates.

Authors:  I Brotherick; B K Shenton; T W Lennard
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

3.  Akt kinases in breast cancer and the results of adjuvant therapy.

Authors:  Olle Stål; Gizeh Pérez-Tenorio; Linda Akerberg; Birgit Olsson; Bo Nordenskjöld; Lambert Skoog; Lars Erik Rutqvist
Journal:  Breast Cancer Res       Date:  2003-01-20       Impact factor: 6.466

4.  The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials.

Authors:  Elin Karlsson; Gizeh Pérez-Tenorio; Risul Amin; Josefine Bostner; Lambert Skoog; Tommy Fornander; Dennis C Sgroi; Bo Nordenskjöld; Anna-Lotta Hallbeck; Olle Stål
Journal:  Breast Cancer Res       Date:  2013       Impact factor: 6.466

5.  The role of microRNA-200 in progression of human colorectal and breast cancer.

Authors:  Linda Bojmar; Elin Karlsson; Sander Ellegård; Hans Olsson; Bergthor Björnsson; Olof Hallböök; Marie Larsson; Olle Stål; Per Sandström
Journal:  PLoS One       Date:  2013-12-20       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.